11 Lymphoma Clinical Trials in Nashville, TX (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Lymphoma Studies in Nashville

NCT07634471Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers wa...

Nashville, TX960 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

Nashville, TX255 participantsArvinas Inc.

View Study Details

NCT07519772Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL i...

Nashville, TX200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07082803Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies i...

Nashville, TX180 participantsTreeline Biosciences, Inc.

View Study Details

NCT07284433Recruiting

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy use...

Nashville, TX178 participantsAvenCell Therapeutics, Inc.

View Study Details

NCT07439653Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL...

Nashville, TX155 participantsTORL Biotherapeutics, LLC

View Study Details

NCT06733441Recruiting

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma....

Nashville, TX50 participantsTreeline Biosciences, Inc.

View Study Details

NCT05296070Recruiting

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell can...

Nashville, TX50 participantsUniversity of Miami

View Study Details

NCT07121946Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity...

Nashville, TX42 participantsLTZ Therapeutics, Inc.

View Study Details

NCT04561206Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not r...

Nashville, TX31 participantsCity of Hope Medical Center

View Study Details

NCT07003295Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvem...

Nashville, TX20 participantsNational Cancer Institute (NCI)

View Study Details

About Lymphoma Clinical Trials in Nashville

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 11 lymphoma clinical trials recruiting participants in Nashville, TX. These studies are seeking a combined 2,121 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Arvinas Inc., Treeline Biosciences, Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Nashville — FAQ

Are there lymphoma clinical trials in Nashville?

Yes, there are 11 lymphoma clinical trials currently recruiting in Nashville, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 11 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 13, 2026 from ClinicalTrials.gov